Shots:
- Akeso has dosed its first patient with cadonilimab + lenvatinib in P-II (COMPASSION-36/AK104-225) trial against lenvatinib for the treatment of advanced HCC in pts previously treated with Tecentriq & Avastin; study is ongoing in the US, EU & China
- Cadonilimab has also shown superior efficacy in combination regimens, incl. 100% DCR with FOLFOX-HAIC in resectable multinodular HCC (ESMO Asia’23), improved 1L efficacy with lenvatinib in advanced HCC (ESMO’23), & superior results in IO-resistant lung cancer with pulocimab (WCLC’25)
- Also, enrollment for P-III trial of cadonilimab as adj. therapy for high-risk recurrent HCC post-surgery is complete, & a P-III study with lenvatinib + TACE in intermediate/adv. unresectable HCC is ongoing
Ref: PRNewswire | Image: Akeso |Press Release
Related News:- Akeso Reports First Patient Dosing in P-III (COMPASSION-33) Trial of Cadonilimab for G/GEJ Adenocarcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
